Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMT-676 in Advanced Solid Tumors
NCT06400485Phase 1Recruiting
- Sponsor
- Multitude Therapeutics
- Start
- Jun 2024
- Primary completion
- May 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of AMT-676 in solid tumor (advanced stage), sponsored by Multitude Therapeutics. Primary endpoints: Recommended Phase 2 Dose, Maximum Tolerated Dose and 1 more. Started Jun 2024; status: recruiting.
02
Drugs
AMT-676
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06400485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06400485.